AU5619400A - Statine-derived tetrapeptide inhibitors of beta-secretase - Google Patents

Statine-derived tetrapeptide inhibitors of beta-secretase

Info

Publication number
AU5619400A
AU5619400A AU56194/00A AU5619400A AU5619400A AU 5619400 A AU5619400 A AU 5619400A AU 56194/00 A AU56194/00 A AU 56194/00A AU 5619400 A AU5619400 A AU 5619400A AU 5619400 A AU5619400 A AU 5619400A
Authority
AU
Australia
Prior art keywords
statine
secretase
beta
tetrapeptide inhibitors
derived tetrapeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU56194/00A
Other languages
English (en)
Inventor
Lawrence Fang
Varghese John
Shumeye S. Mamo
Jay Tung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Publication of AU5619400A publication Critical patent/AU5619400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU56194/00A 1999-06-15 2000-06-15 Statine-derived tetrapeptide inhibitors of beta-secretase Abandoned AU5619400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13917399P 1999-06-15 1999-06-15
US60139173 1999-06-15
PCT/US2000/016643 WO2000077030A1 (en) 1999-06-15 2000-06-15 Statine-derived tetrapeptide inhibitors of beta-secretase

Publications (1)

Publication Number Publication Date
AU5619400A true AU5619400A (en) 2001-01-02

Family

ID=22485425

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56194/00A Abandoned AU5619400A (en) 1999-06-15 2000-06-15 Statine-derived tetrapeptide inhibitors of beta-secretase

Country Status (5)

Country Link
EP (1) EP1192177A1 (de)
JP (1) JP2003502342A (de)
AU (1) AU5619400A (de)
CA (1) CA2376420A1 (de)
WO (1) WO2000077030A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1196609A2 (de) 1999-06-28 2002-04-17 Oklahoma Medical Research Foundation Katalytisch wirksame rekombinierte memapsin und verfahren zur verwendung davon
EP1666452A2 (de) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Verbindungen zur Behandlung der Alzheimerischen Krankheit
WO2002100856A1 (en) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
MXPA04000328A (es) 2001-07-10 2004-07-23 Pharmacia & Upjohn Comapny Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.
AU2002359301B2 (en) 2001-10-23 2008-07-03 Comentis, Inc. Beta-secretase inhibitors and methods of use
MXPA04005428A (es) 2001-12-06 2004-12-06 Elan Pharm Inc Hidroxietilaminas substituidas.
JP2005534614A (ja) * 2002-01-04 2005-11-17 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病治療のための置換アミノカルボキサミド
AU2003229024A1 (en) 2002-05-07 2003-11-11 Elan Pharmaceuticals, Inc. Succinoyl aminopyrazoles and related compounds
US7557137B2 (en) * 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
PE20040762A1 (es) 2002-11-27 2004-11-06 Elan Pharm Inc Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
JP4540606B2 (ja) * 2003-02-28 2010-09-08 良明 木曽 βセクレターゼ阻害活性を有するペプチド誘導体
US20050090449A1 (en) * 2003-05-13 2005-04-28 Boehringer Ingelheim International Gmbh Novel statine derivatives for the treatment of Alzheimer's disease
EP2511267A1 (de) 2003-06-05 2012-10-17 Elan Pharmaceuticals Inc. 3-((n-acylierte aminoacyl)amino)pyrazole als inhibitoren der beta-amyloid-peptid-production useful verwendbar für die behandlung von alzheimerskrankheit
WO2006050861A2 (en) * 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
WO2006050862A1 (en) 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
CN101348456B (zh) * 2007-07-17 2011-05-11 中国科学院上海药物研究所 苄基哌啶类化合物及其制备方法和用途
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
EP2281824A1 (de) 2009-08-07 2011-02-09 Noscira, S.A. Furan-Imidazolon-Derivate zur Behandlung von kognitiven, neurodegenerativen oder neuronalen Erkrankungen oder Funktionsstörungen
WO2012069428A1 (en) 2010-11-22 2012-05-31 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions

Also Published As

Publication number Publication date
JP2003502342A (ja) 2003-01-21
CA2376420A1 (en) 2000-12-21
EP1192177A1 (de) 2002-04-03
WO2000077030A1 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
AU5619400A (en) Statine-derived tetrapeptide inhibitors of beta-secretase
AU8875798A (en) Meta-benzamidine derivatives as serin protease inhibitors
AU6762400A (en) Inhibitors of factor xa
AU5283800A (en) Inhibitors of factor xa
AU5283700A (en) Inhibitors of factor xa
AU5283900A (en) Inhibitors of factor xa
AU3857300A (en) Inhibitors of factor xa
AU6111000A (en) Inhibitors of viral helcase
AU1536799A (en) Bishydroxyureas as inhibitors of the 5-lipoxygenase
AU5284000A (en) Inhibitors of factor xa
AU3074500A (en) Proteasome inhibitors
AU3124300A (en) Inhibitors of beta-lactamases and uses therefor
AU2190400A (en) Inhibitors of beta-lactamases and uses therefor
AU2723099A (en) Tryptase inhibitors
AU7126900A (en) Enzyme inhibitors
AU2578200A (en) Jammer
AU3235100A (en) Prothease inhibitors
GB9924522D0 (en) Enzyme inhibitors
AU1588901A (en) Protease inhibitors
AU1474801A (en) Protease inhibitors
AU1176299A (en) Tryptase inhibitors comprising heterocyclic amide compounds
AU3888200A (en) Protease inhibitors
AU1474701A (en) Protease inhibitors
AU1474601A (en) Protease inhibitors
AU4066900A (en) Protease inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase